The Regulatory Framework of Virus Filtration

The Regulatory Framework of Virus Filtration

Many biopharmaceutical therapies, such as mAbs and blood plasma factors, are produced using biological materials. This carries the risk that microorganisms such as viral contaminants may be unintentionally introduced into the manufacturing process and contaminate the product.  Thus of paramount importance is the removal of such adventitious agents using effective viral filtration methods.

 

In this webinar, the fundamental principles of virus filtration as well as its practical execution will be discussed.  In addition, participants will gain an in-depth understanding of filterability, validation and the local regulatory framework surrounding virus filtration processes.  By the conclusion of the session, all attendees should be able to conduct a virus filterability trial and will be well equipped to have appropriate discussions with validation labs.

 

Participants will learn:

  • Regulatory framework
  • Principles of virus filtration
  • How to maximize virus safety at minimized cost
  • How to validate continuous viral clearance process

Speaker

 

 

Morven McAlister Ph.D.

Global Sr. Director, Regulatory and Validation Consultancy

Pall Biotech

Dr Morven McAlister is the Global Senior Director of the Regulatory and Validation Consultancy team at Pall Biotech. She is currently involved in using Quality by Design (QbD) principles for new process applications, product, and method development, as well as supporting microbial risk mitigation practices for end-users. She is also actively involved in various industry task forces (e.g. BPOG, PDA, ASTM) to standardize methods and technical positioning around microbial contamination control.

Biography

Learn how Pall's Accelerator Validation Services Can Support You on Your Validation Journey

Download the brochure to read about Pall's depth of validation expertise, consultancy services, testing capabilities and analytical methods

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
April 2022
Getting Ready for SUT X-Ray Irradiation

Biotech | Pall Corporation webinar series

Why the introduction of X-ray sterilization technology is a critical change for single-use industry, and how gamma and X-ray irradiation compare

 

The market demand for gamma irradiation, the current primary method for the sterilization in SUT, will soon significantly exceed supply, creating an urgent need for alternatives.

 

Join Christelle Marcoux from GSK Vaccines (BioPhorum workstream member on alternatives to gamma sterilization) and James Hathcock, PhD of Pall Corporation (Bio-Process Systems Alliance X-Ray Committee Co-Chair) as they discuss the introduction of X-ray sterilization technology.

 

You will learn more about:

 

  • Why this is a critical change for industry and the responsibilities of each stakeholder
  • Key questions to address for biomanufacturers
  • How gamma and X-ray irradiation compare
  • What testing has been completed and key milestones for readiness for industry
  • An example of how to qualify a SUS sterilized with X-ray irradiation
Watch